CARLSBAD, Calif.--(BUSINESS WIRE)--Invitrogen, a division of Life Technologies (NASDAQ:LIFE), today announced the launch of GIBCO® OpTmizer™ T-cell Expansion SFM, a next-generation solution for culturing and expanding human T-cells that does not require the addition of serum to achieve optimal, cost-efficient results. OpTmizer SFM will enable scientists to advance their research on the central role that T-cells play in human immune response. These cells are widely studied by scientists conducting basic and clinical research, as well as biotech and pharmaceutical companies and organizations studying biodefense.
